Drug Repurposing: Scopes in Herbal/Natural Products-based Drug Discovery and Role of in silico Techniques
Abstract
Natural products and their derivatives are the most promising and prolific resources in identifying the therapeutic small compounds with potential therapeutic activity. Nowadays, working with herbal or natural products can be boosted by collecting the data available for their chemical, pharmacological, and biological characteristics properties. Using in silico tools and methods, we can enhance the chances of getting a better result in a precise way. It can support experiments to emphasis their sources in fruitful directions. Though due to their limitations with respect to current knowledge, quality, quantity, relevance of the present data as well as the scope and limitations of cheminformatics methods, herbal product-based drug discovery is limited. The pharmaceutical re-profiling is done with the main objective to establish strategies by using approved drugs and rejected drug candidates in the diagnosis of new diseases. Drug repurposing offers safety lower average processing cost for already approved, withdrawn drug candidates. In silico methods could be oppressed for discovering the actions of un-investigated phytochemicals by identification of their molecular targets using an incorporation of chemical informatics and bioinformatics along with systems biological approaches, hence advantageous for small-molecule drug identification. The methods like rule-based, similarity-based, shape-based, pharmacophore-based, and network-based approaches and docking and machine learning…
How strong is the evidence?
Evidence Hub reads this as a book / chapter, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.